share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4：持股變動聲明-董事 Dar Zavain
美股sec公告 ·  06/06 06:17
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. (RXRX) reported that Dar Zavain, a person associated with the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction was completed at no cost to the recipient, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Zavain's direct holdings in the company increased to a total of 102,153 shares. The grant is part of the company's ongoing efforts to align the interests of its key personnel with those of its shareholders.
Recursion Pharmaceuticals, Inc. (RXRX) reported that Dar Zavain, a person associated with the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction was completed at no cost to the recipient, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Zavain's direct holdings in the company increased to a total of 102,153 shares. The grant is part of the company's ongoing efforts to align the interests of its key personnel with those of its shareholders.
Recursion Pharmaceuticals, Inc.（RXRX）報告了公司相關人員Dar Zavain在2024年6月3日獲準獲得13,097股A類普通股。此交易對受贈人沒有任何費用，表明這些股票可能作為補償方案或激勵計劃的一部分授予。此次交易後，Zavain持有該公司的直接持股增至總共102,153股。這次授予是該公司為了將關鍵人員的利益與股東的利益相結合而進行的持續努力。
Recursion Pharmaceuticals, Inc.（RXRX）報告了公司相關人員Dar Zavain在2024年6月3日獲準獲得13,097股A類普通股。此交易對受贈人沒有任何費用，表明這些股票可能作為補償方案或激勵計劃的一部分授予。此次交易後，Zavain持有該公司的直接持股增至總共102,153股。這次授予是該公司為了將關鍵人員的利益與股東的利益相結合而進行的持續努力。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。